Summary Mutations in the p53 tumour-suppressor gene are among the most common genetic alterations in human cancers. In the present study we analysed the mutations in the p53 tumor-suppressor gene in 25 primary and 20 metastatic human prostate cancer specimens. DNA extracted from the paraffin-embedded sections was amplified by hot-start polymerase chain reaction, and p53 gene mutations in the conserved mid-region (exons 4-9) were examined using single-strand conformation polymorphism (SSCP) analysis and immunohistochemistry. In the present study, we used a novel hot-start PCR-SSCP technique using DNA Taq polymerase antibody, which eliminates primer-dimers and non-specific products. (Dinjens et al., 1994 , Peehl, 1993 , Carter 1990 Procedure for conventional PCR Paraffin-embedded prostate cancer specimens were used for the extraction of DNA. About 5-6 gm sections from prostatic carcinoma tissues were cut and stained with haematoxylin and eosin. All sections were reviewed by a pathologist. For this purpose the samples containing no carcinoma were considered normal, and the presence of carcinoma was confirmed histologically. Genomic DNA was extracted and quantified from these tissues as described earlier (Gao et al., 1995; Dahiya et al., 1995a 
Mutations in the p53 tumour-suppressor gene, located on chromosome 17p13, are the most frequently observed alterations in human cancer (Hollstein et al., 1991) . The p53 mutations can be in one of the four domains of the protein: NH2-terminal transactivation domain, a central DNA binding domain, an oligomerisation domain, and a basic COOH-terminal nuclear localisation domain (Clore et al., 1994) . In this regard Harris and Hollstein (1993) have reported that most p53 mutations found in human cancers are located within the DNA-binding domain. The wild-type p53 protein has a short half-life and cannot be detected by immunohistochemical methods. However, mutated p53 has a considerably expanded half-life and is detectable immunohistochemically. Therefore, p53 staining in tissue sections is indicative of mutant p53 protein.
Prostate cancer is the most common neoplasm in western countries. Despite its high incidence, relatively few investigations have attempted to unravel the genetic alterations (e.g. tumour-suppressor genes and oncogenes) that might play a role in understanding the pathophysiology and regulation of prostate cancer (Dinjens et al., 1994 , Peehl, 1993 , Carter 1990 . The mechanisms responsible for p53 inactivation include gene deletion, somatic and germline point mutations, inactivation of proteins encoded by DNA tumour viruses, such as the E6 protein of human papilloma viruses and SV 40 large T antigen which bind to and neutralise the function of p53 protein through various mechanisms (Malkin et al., 1990; Mietz et al., 1992; Dutta et al., 1992) . p53 can also mediate transcriptional activation of genes containing at least two copies of a 10 bp sequence motif that constitutes a specific binding site for this protein Kern et al., 1992; Scharer and Iggo, 1993) . In some cases the down-regulation may be via interactions of p53 with TATAbinding factor involved in transcription initiation in genes that contain a TATAA box (Mack et al., 1993) . In a recent study, Miyashita et al. (1994) Procedure for conventional PCR Paraffin-embedded prostate cancer specimens were used for the extraction of DNA. About 5-6 gm sections from prostatic carcinoma tissues were cut and stained with haematoxylin and eosin. All sections were reviewed by a pathologist. For this purpose the samples containing no carcinoma were considered normal, and the presence of carcinoma was confirmed histologically. Genomic DNA was extracted and quantified from these tissues as described earlier (Gao et al., 1995; Dahiya et al., 1995a (Mullins and Faloona, 1987) .
Procedure for hot-start PCR using DNA Taq polymerase antibody Before the reaction mixture first reaches high temperature, non-specific hybridisation and primer-dimers have already been formed owing to the low-level activity of Taq DNA polymerase at room temperature. These non-specific products can be amplified during the thermal cycling, leading to lowered yield of the desired products and multiple non-specific bands. To overcome this non-specific amplification, Taq DNA polymerase and the antibody against Taq DNA polymerase (TaqStart antibody, Clontech, Palo Alto, CA, USA) were added to the complete PCR reaction mixture, heated to 94°C and processed to thermal cycling as described under conventional PCR section (Dahiya et al., 1995a; Sharkey et al., 1994) . When Taq DNA polymerase is mixed with Taq polymerase antibody, the non-specific products and primer-dimers are eliminated because the activity of Taq DNA polymerase is blocked by the antibody during assembly of the reaction mixture at room temperature. When the PCR solution is heated to high temperature (>70'C), the Taq DNA polymerase is released, and only specific products are produced at high temperature (Dahiya et al., 1995a) .
Single-stranded conformation polymorphism (SSCP) Genomic DNA was isolated from five consecutive 5 gim sections and amplified by hot-start polymerase chain reaction (using TaqStart antibody, Clontech). The reaction mixture containing template, 1 pCi [a-32P]dCTP, and primers was amplified by hot-start PCR (p53 exons 5-9 primers see Table  1 ), and the generated fragment was denatured and analysed by 6% polyacrylamide gel electrophoresis at room temperature. The separated DNA strands were visualised by autoradiography and abnormally migrating SSCP bands were observed.
Sequencing
The hot-start PCR-generated fragments of exon 7 of the p53 gene for wild-type and prostate cancer (C3) were denatured and sequenced using the Sequenase version 2.0 DNA sequencing kit (US Biochemical, Cleveland, OH, USA) and [35S]dATP (Amersham, Arlington Heights, IL, USA) and p53 primers (see Table I ). Genomic DNA from control samples containing wild-type p53 alleles was sequenced in parallel when confirming mutations in samples that were positive for p53 in the PCR-SSCP analysis.
Immunohistochemistry Paraffin-embedded sections (5 pm) of prostatic specimens were deparaffinised in 10 mM citric acid, pH 6 and microwaved for 10 min. The primary antibody [mouse antihuman p53, clone al., 1989, 1992, 1995b) .
Results and discussion
In the present study, we have examined 25 primary and 20 metastatic human prostate cancer specimens for p53 mutations by hot-start PCR-SSCP analysis, followed by sequencing of the exon fragment with abnormally migrating SSCP bands. We also examined the p53 protein expression by immunohistochemistry using PAb 1801, which detects both wild-type and mutated p53. The results of these experiments are discussed below.
The sequences of p53 primers used for PCR in this present 300 bp 200 bp 100 bp- Figure 1 Hot-start PCR using p53 exon 6 primers in human prostatic cancer. Genomic DNA (100 g) was amplified by hotstart PCR using TaqStart antibody and exon 6 primers. The products were separated on a 2% agarose gel and the product size was 166 bp for p53 exon 6 primers.
-166 bp superior technique than the regular SSCP (Dahiya et al., 1995b) . The exclusion of PCR contamination in prostate cancer samples was checked by using DNA negative controls. Figure 5 shows the PCR-SSCP analysis of p53 exon 7 from prostate cancer DNA. Lanes 5 and 6 show highly distinct migrating bands in SSCP analysis, suggesting the presence of mutation in these samples. Lanes 1, 2, 3, 4 and 7 did not show any mutation. There were 8% mutations of p53 exon 7 in primary prostate cancer (2 out of 25 samples) and 20% mutations in lymph node metastatic prostate cancer (4 out of 20 samples). There was no mutation in p53 exons 8 and 9 in prostate cancer DNA. The results of these experiments suggest that p53 mutations were exclusively in exon 7 and not in exons 4, 5, 6, 8 or 9. Prior studies (Dinjens et al., 1994; Navone et al., 1993) Exon 7 Figure 5 Autoradiogram of SSCP analysis of prostate cancer specimens for exon 7 of the p53 gene. Lanes 1-7 show denatured products of hot-start SSCP reaction analysed on 6% polyacrylamide gel. The shifted bands in lanes 5 and 6 (arrow) show the mutation at exon 7 of the p53 gene. The shift in band is very clear because of our new hot-start SSCP technique. Hot-start PCR-generated fragments of exon 7 of p53 gene from wild-type and prostate cancer tissues were denatured and sequenced using the Sequenase kit. PCR-SSCP technique, which is a much more specific and reliable method; (2) based on the number of samples analysed in this study, p53 mutations were found only in exon 7, but if more samples were to be analysed then we may detect mutations in other exons. The biological function of p53 is not yet completely understood, but the recent data indicate that p53 is a transcriptional factor, which plays an important role in cell cycle control and apoptosis. Wild-type p53 has been shown to inhibit transformation by activated oncogenes in cell culture, can inhibit growth of tumour cells in vitro and can prevent tumour formation in animal models (Finlay et al., 1989; Eliyahu et al., 1989; Baker et al., 1990; Chen et al., 1990) . Furthermore, transgenetic mice lacking p53 are prone to the spontaneous development of tumours at a very early stage, suggesting a significant role of p53 in preventing cancer (Donehower et al., 1992) . Prior studies (Xiong et al., 1993; Dulic et al., 1994) have shown that p53 protein is believed to exert its tumour-suppressor activity by stimulating the transcription of the p21 gene product that in turn inhibits cyclin-dependent kinase 4, thereby blocking cell division. p53 mutations may therefore constitute one of the few oncogenic alterations that increase rather than decrease the sensitivity of cells to anti-tumour agents . Figure 6 shows the p53 gene mutation site in the prostate cancer tissues. Hot-start PCR-generated fragments of exon 7 of p53 gene from wild-type and prostate cancer tissues were denatured and sequenced using the Sequenase kit. Figure 6a shows the sequencing (antisense direction) of the wild-type sample and figure 6b shows Figure 7 shows the immunohistochemical staining of p53 in prostate cancer tissue using PAb 1801, which detects both wild-type and mutated p53 protein. All the specimens were stained with PAb 1801 antibody and compared to determine whether immunohistochemistry reliably detects overexpression of p53 as a result of mutation. All six specimens with p53 mutations showed nuclear staining in more than 40% of the metastatic prostate cancer cells in each specimen. Our immunohistochemical data confirm and extend the findings of other investigators (Thompson et al., 1992; Visakorpi et al., 1992; Dinjens et al., 1994) . However, Van Veldhuizen et al. (1993) showed increased cytoplasmic p53 staining in more than 79% of prostate cancer tissues but this study did not confirm mutations by structural analysis of the p53 gene. Taken together, these experiments suggest that the p53 gene mutations are a late event in the progression of prostatic cancer and are associated with metastatic stage, loss of differentiation and transition from androgen-dependent to androgen-independent growth.
